Brick Claudia, Leet Angeline, Tay Hui, Kaye David M, Taylor Andrew J
Department of Cardiology, Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia.
Department of Pathology, Alfred Hospital, Melbourne, Victoria, Australia.
Eur Heart J Case Rep. 2024 Aug 22;8(10):ytae409. doi: 10.1093/ehjcr/ytae409. eCollection 2024 Oct.
Fulminant eosinophilic myocarditis (EM) is a rare and often fatal condition that may present atypically and be complicated by ventricular arrhythmias. Treatment involves high-dose corticosteroids to suppress eosinophilia, as well as increasing use of mepolizumab, an anti-interleukin-5 antibody with evidence for long-term efficacy and safety.
A 38-year-old woman presented to the emergency department with neck pain and fatigue, and after extensive investigation was diagnosed with EM secondary to idiopathic hypereosinophilic syndrome. The patient was treated with methylprednisolone for eosinophil suppression and warfarin due to the presence of biventricular apical thrombi. Despite previously stable haemodynamics, the patient had a cardiac arrest due to ventricular fibrillation on Day 11 of hospitalization, requiring 30 min of cardiopulmonary resuscitation and commencement of veno-arterial extracorporeal membrane oxygenation support due to refractory ventricular arrhythmias. The patient was urgently listed for heart transplant but a suitable match was not identified, and she was weaned to pharmacologic support on Day 34. The patient survived with minimal sequelae and has returned to full-time work. She remains on mepolizumab as a steroid-sparing agent, therapeutic anti-coagulation, and heart failure therapy.
This report describes an atypical presentation of fulminant EM requiring weeks of mechanical circulatory support due to refractory arrhythmia rather than heart failure. The case also highlighted the benefits of non-invasive cardiac magnetic resonance imaging in both diagnosis and prognostication of EM, as well as the need to maintain a high index of suspicion for this rare disease.
暴发性嗜酸性粒细胞性心肌炎(EM)是一种罕见且常致命的疾病,其表现可能不典型,并伴有室性心律失常并发症。治疗包括使用高剂量皮质类固醇抑制嗜酸性粒细胞增多,以及越来越多地使用美泊利单抗,这是一种抗白细胞介素-5抗体,有长期疗效和安全性的证据。
一名38岁女性因颈部疼痛和疲劳就诊于急诊科,经过广泛检查后被诊断为特发性高嗜酸性粒细胞综合征继发的EM。患者接受甲泼尼龙治疗以抑制嗜酸性粒细胞,并因双心室心尖血栓而使用华法林。尽管此前血流动力学稳定,但患者在住院第11天因室颤发生心脏骤停,因难治性室性心律失常需要进行30分钟的心肺复苏并开始静脉-动脉体外膜肺氧合支持。患者被紧急列入心脏移植名单,但未找到合适的配型,在第34天撤机至药物支持。患者存活下来,后遗症极少,已恢复全职工作。她继续使用美泊利单抗作为类固醇节约剂、治疗性抗凝剂和心力衰竭治疗药物。
本报告描述了暴发性EM的非典型表现,由于难治性心律失常而非心力衰竭需要数周的机械循环支持。该病例还强调了无创心脏磁共振成像在EM诊断和预后评估中的益处,以及对这种罕见疾病保持高度怀疑的必要性。